theThe Effects of Zoledronic Acid Treatment on Depression and Quality of Life in the Women with Postmenopausal Osteoporosis: A Clinical Trail Study

Osteoporosis affects quality of life and may lead to depression in women. The purpose of this study was to evaluate the effects of zoledronic acid (ZA) treatment on depression and quality of life (QoL) in women with postmenopausal osteoporosis (PO).
A total of 88 newly diagnosed women with PO were included in this study. All patients were treated with once-yearly ZA (5 mg). A quality of life questionnaire from the European Foundation for Osteoporosis (QUALEFFO) and Beck Depression Inventory (BDI) were given to patients at baseline and at twelve months. The results for baseline and post-twelfth month were compared and bone mineral density (BMD) levels were compared.
the consumption of Once-yearly ZA( 5 mg) treatment increases bone mineral density (BMD) at levels of lumbers 1-4 (p:0.026), total hip, and femoral neck (p:0.033). ZA 5mg treatment also improved QoL (p:0.001) and reduced depression (p:0.001).
Zoledronic acid treatment increases BMD levels and QoL while reducing depression. Once-yearly ZA (5 mg) may be considered for postmenopausal women as a first-line treatment.